Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 2/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | L1CAM | P32004 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4218154 | 0.94 | CA1 (0.65) | TERTALOX5CA1CA9L1CAM | |
| SCHEMBL9674654 | 0.92 | TERT (0.56) | TERTALOX5CA1CA9L1CAM | |
| SCHEMBL723254 | 0.84 | TERT (0.61) | TERTALOX5CA1CA9KDM4E | |
| SCHEMBL32018464 | 0.84 | TERT (0.61) | TERTALOX5CA1CA9KDM4E | |
| SCHEMBL1436240 | 0.84 | GAA (0.69) | TERTALOX5CA1NPC1KDM4E | |
| SCHEMBL4235075 | 0.84 | LMNA (0.61) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4230145 | 0.84 | KMT2A (0.63) | TERTNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL4223765 | 0.83 | TLR7 (0.60) | TERTALOX5CA1CA9L1CAM | |
| SCHEMBL23117963 | 0.83 | ALOX5 (0.59) | TERTALOX5CA1CA9NPC1 | |
| SCHEMBL8983169 | 0.83 | ALOX5 (0.59) | TERTALOX5CA1CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009026248-A2 | HYDRAZIDE, AMIDE, PHTHALIMIDE AND PHTHALHYDRAZIDE ANALOGS AS INHIBITORS OF RETROVIRAL INTEGRASE | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH, OFFICE OF TECHNOLOGY TRANSFER (US) | 2009-02-26 | — | — | WO | claimed |
| US-20140243348-A1 | COMPOSITIONS AND METHODS FOR TREATING HERPES VIRUSES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243348-A1 | COMPOSITIONS AND METHODS FOR TREATING HERPES VIRUSES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013028297-A1 | COMPOSITIONS AND METHODS FOR TREATING HERPES VIRUSES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-28 | — | — | WO | disclosed |
| WO-2009026248-A2 | HYDRAZIDE, AMIDE, PHTHALIMIDE AND PHTHALHYDRAZIDE ANALOGS AS INHIBITORS OF RETROVIRAL INTEGRASE | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH, OFFICE OF TECHNOLOGY TRANSFER (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009026248-A2 | HYDRAZIDE, AMIDE, PHTHALIMIDE AND PHTHALHYDRAZIDE ANALOGS AS INHIBITORS OF RETROVIRAL INTEGRASE | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH, OFFICE OF TECHNOLOGY TRANSFER (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243348-A1 | COMPOSITIONS AND METHODS FOR TREATING HERPES VIRUSES | EBNA1BP2, RPL17, TK2 | TERT 1005/4885ALOX5 1132/4885CA1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.